BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 17892973)

  • 1. Continuous oral contraception: changing times.
    Sulak PJ
    Best Pract Res Clin Obstet Gynaecol; 2008 Apr; 22(2):355-74. PubMed ID: 17892973
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recent innovations in oral contraception.
    Cremer M; Phan-Weston S; Jacobs A
    Semin Reprod Med; 2010 Mar; 28(2):140-6. PubMed ID: 20391327
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Oral contraception].
    Montloin A
    Rev Infirm; 1990 Nov; 40(18):46-52. PubMed ID: 2091202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Reducing the frequency of menses: extended contraception, a review].
    This P
    Gynecol Obstet Fertil; 2013 Jun; 41(6):381-7. PubMed ID: 23769012
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Residual function in the ovary during low-dose oral contraceptive treatment].
    Pearson S; Skouby SO
    Ugeskr Laeger; 1989 Jun; 151(23):1465-8. PubMed ID: 2734951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Greater inhibition of the pituitary--ovarian axis in oral contraceptive regimens with a shortened hormone-free interval.
    Willis SA; Kuehl TJ; Spiekerman AM; Sulak PJ
    Contraception; 2006 Aug; 74(2):100-3. PubMed ID: 16860046
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The use of triphasic oral contraceptives in a continuous use regimen.
    Shulman LP
    Contraception; 2005 Aug; 72(2):105-10. PubMed ID: 16022848
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Benefits and risk of the modern combined hormonal contraception].
    Fait T; Nouzová K; Sýkorová P; Fanta M; Vrablík M; Skrenková J
    Cas Lek Cesk; 2005; 144(4):238-44. PubMed ID: 15945482
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Menstrual-cycle-related symptoms: a review of the rationale for continuous use of oral contraceptives.
    Archer DF
    Contraception; 2006 Nov; 74(5):359-66. PubMed ID: 17046376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pituitary-ovarian hormone levels and symptoms in oral contraceptive users: comparison of a 21/7-day and extended regimen.
    Kuehl TJ; Speikermann AM; Willis SA; Coffee A; Sulak PJ
    J Reprod Med; 2008 Apr; 53(4):266-70. PubMed ID: 18472649
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Why Stop Now? Extended and Continuous Regimens of Combined Hormonal Contraceptive Methods.
    Benson LS; Micks EA
    Obstet Gynecol Clin North Am; 2015 Dec; 42(4):669-81. PubMed ID: 26598308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral contraceptive tolerance: does the type of pill matter?
    Moreau C; Trussell J; Gilbert F; Bajos N; Bouyer J
    Obstet Gynecol; 2007 Jun; 109(6):1277-85. PubMed ID: 17540798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rationale for eliminating the hormone-free interval in modern oral contraceptives.
    London A; Jensen JT
    Int J Gynaecol Obstet; 2016 Jul; 134(1):8-12. PubMed ID: 27067074
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extended cycle combined hormonal contraception.
    Steinauer J; Autry AM
    Obstet Gynecol Clin North Am; 2007 Mar; 34(1):43-55, viii. PubMed ID: 17472864
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Lowering the steroid dose in oral contraception and risk of functional ovarian cysts].
    Mayenga JM; Segard L; Cohen J; Belaïsch-Allart J
    Contracept Fertil Sex; 1995; 23(7-8):439-41. PubMed ID: 7550556
    [No Abstract]   [Full Text] [Related]  

  • 17. The phasic approach to oral contraception: the triphasic concept and its clinical application.
    Upton GV
    Int J Fertil; 1983; 28(3):121-40. PubMed ID: 6140231
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Headaches and oral contraceptives: impact of eliminating the standard 7-day placebo interval.
    Sulak P; Willis S; Kuehl T; Coffee A; Clark J
    Headache; 2007 Jan; 47(1):27-37. PubMed ID: 17355491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Progestin and estrogen potency of combination oral contraceptives and endometrial cancer risk.
    Maxwell GL; Schildkraut JM; Calingaert B; Risinger JI; Dainty L; Marchbanks PA; Berchuck A; Barrett JC; Rodriguez GC
    Gynecol Oncol; 2006 Nov; 103(2):535-40. PubMed ID: 16740300
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term assessment of symptomatology and satisfaction of an extended oral contraceptive regimen.
    Coffee AL; Sulak PJ; Kuehl TJ
    Contraception; 2007 Jun; 75(6):444-9. PubMed ID: 17519150
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.